Standard Biotools (LAB) Receivables - Net (2010 - 2026)

Standard Biotools (LAB) has 17 years of Receivables - Net data on file, last reported at $16.6 million in Q1 2026.

• Quarterly Receivables - Net fell 53.11% year-over-year to $16.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.6 million (down 53.11% YoY) and the FY2025 annual result came in at $13.7 million, down 8.57% from the prior year.
• Receivables - Net rose to $16.6 million in Q1 2026 per LAB's latest filing, from $13.7 million in the prior quarter.
• Across five years, Receivables - Net topped out at $36.0 million in Q1 2024 and bottomed at $10.9 million in Q2 2022.
• The 5-year median for Receivables - Net is $16.6 million (2023), against an average of $20.0 million.
• The widest annual swing landed in 2024, when Receivables - Net surged 148.29%; it then sank 60.55% in 2025.
• Tracing LAB's Receivables - Net over 5 years: stood at $17.3 million in 2022, then climbed by 15.58% to $20.0 million in 2023, then fell by 24.89% to $15.0 million in 2024, then slipped by 8.57% to $13.7 million in 2025, then grew by 21.31% to $16.6 million in 2026.
• Per Business Quant, the three latest LAB Receivables - Net figures stand at $16.6 million (Q1 2026), $13.7 million (Q4 2025), and $13.9 million (Q3 2025).

Peer Comparison